PEPTIDE MANUFACTURING | FROM SPPS TO FERMENTATION — THE NEXT TECHNOLOGY SHIFT?
THE CURRENT MODEL — SPPS
- SPPS (Solid-Phase Peptide Synthesis) remains the dominant peptide manufacturing platform.
- Peptide is built step-by-step on a resin, with repeated amino-acid coupling, deprotection and washing cycles.
- The process is highly flexible and proven for complex peptides.
- Major drawback: extremely high solvent and material consumption.
- Large-scale assessments indicate SPPS Process Mass Intensity (PMI) of ~13,000, meaning ~13,000 kg of total inputs can be required per 1 kg of peptide.
- Solvents and repeated resin washing are major contributors to waste.
PURIFICATION — ANOTHER MAJOR CHALLENGE
- Post-synthesis material contains the desired peptide along with closely related impurities.
- Preparative chromatography is therefore required for purification.
- Downstream purification can account for roughly half of PMI in some peptide processes.
- Highly dilute processing and large solvent requirements make purification both expensive and resource-intensive.
LPPS — AN ALTERNATIVE ROUTE
- LPPS (Liquid-Phase Peptide Synthesis) performs synthesis in solution rather than on a solid resin.
- Eliminates the solid support and many repetitive resin-washing steps.
- Can potentially reduce solvent consumption and become attractive for larger-scale production.
- Limitation: longer and more complex peptides become increasingly difficult to keep soluble and separate efficiently.
- Therefore, SPPS remains the workhorse for many complex peptides.
FERMENTATION / RECOMBINANT MANUFACTURING — POTENTIAL TECHNOLOGY SHIFT
- Instead of chemically assembling the entire peptide amino acid-by-amino acid, microorganisms such as yeast or bacteria can be engineered to produce the peptide or its precursor.
- Basic process: nutrients → microbial growth → peptide/protein production → recovery → purification → required chemical modifications.
- Potential benefits:
- Fewer protecting-group and coupling steps.
- Lower solvent and chemical-reagent consumption.
- Potentially lower material intensity.
- Potential for better economics at commercial scale.
- However, fermentation does not automatically solve the problem.
- Commercial viability depends on productivity, yield, purity, impurity control, recovery and downstream purification.
INDIAN COMPANIES TO WATCH
ANTHEM BIOSCIENCES
- One of the clearest listed examples combining fermentation and peptide capabilities.
- Fermentation-based specialty APIs include peptides.
- Capabilities span custom synthesis, biotransformation and fermentation.
- Neo Anthem facility includes commercial peptide manufacturing.
- Facility has a 16 KL peptide manufacturing block.
AMOGEN PHARMA
- Direct example of the recombinant-peptide thesis.
- Focuses on recombinant peptides and protein biosimilars.
- Hyderabad platform combines microbial expression and fermentation.
- Highlights GLP-1 programs.
- Plant 1 platform reports 980 kg of GLP-1 fermentation output/capacity.
SANZYME BIOMOLECULES
- Offers peptide manufacturing through multiple routes:
- Solid-phase
- Liquid-phase
- Hybrid
- Recombinant
- Also provides process development and GMP manufacturing.
- Interesting because it can potentially adapt the manufacturing route depending on the molecule.
LAURUS LABS
- Established large-scale fermentation expertise.
- Simultaneously developing commercial peptide manufacturing capabilities.
- Vizag fermentation site adds to the broader fermentation platform.
- Commercial peptide manufacturing could create an important bridge between its existing fermentation capabilities and the emerging peptide opportunity.
CONCORD BIOTECH
- Core strength is fermentation-based APIs.
- More than 1,250 m³ fermentation capacity with substantial downstream recovery infrastructure.
- Management has identified peptides as a potential adjacency.
- However, peptide opportunity should currently be treated as optionality rather than an established commercial peptide-fermentation business.
WHY THIS MATTERS FOR INVESTORS
- Today's peptide investment cycle is heavily focused on SPPS reactors, purification systems, lyophilisers and other conventional infrastructure.
- A large commercial peptide site can require substantial capital investment.
- Raw materials can represent ~60–70% of production cost.
- If fermentation can eventually manufacture complex peptides at meaningfully lower total cost, competitive advantage could shift away from simply having the largest SPPS capacity.
- The key moat could become:
- Microbial strain
- Fermentation process
- Productivity/yield
- Downstream purification
- Process know-how
- Regulatory and commercial-scale execution
POTENTIAL INDUSTRY IMPACT
- Successful fermentation could potentially reduce:
- Protected amino-acid requirements
- Solvent consumption
- Waste-treatment costs
- Plant size requirements
- Capital intensity per kg of peptide
- This could materially change the economics of the peptide value chain over the next 5–10 years.
- Today's capacity race may therefore be only Phase 1.
- Phase 2 could become a race toward biologically manufactured peptides.
INVESTOR FRAMEWORK
- SPPS = proven technology and current workhorse.
- LPPS = potential process-efficiency improvement.
- Fermentation = potential technology disruption.
- The biggest opportunity may belong to companies that combine fermentation expertise with peptide manufacturing and strong downstream purification.
- The key question is not simply who is building the most peptide capacity, but who can eventually manufacture peptides at the lowest cost with consistent quality and commercial scalability.
KEY TAKEAWAY
- SPPS dominates today, but fermentation could reshape peptide manufacturing economics if it achieves lower-cost, scalable commercial production.
8September 3, 2026 1.3K 17
